DCALDishman Carbogen Amcis Ltd.

    Dishman Carbogen Amcis: 59.32% stake to move within promoter group

    • Agreement
    • Pharmaceutical services

    Blacklitt Research2 min read

    Two empty glass test tubes lying on a plain grey surface, one with a few dark specks inside.
    B.Lachner, via Wikimedia Commons (CC0). Illustrative image.

    Dishman Carbogen Amcis (NSE: DCAL) has a share purchase agreement, dated 28 Oct 2026, under which Adimans Technologies LLP will sell its entire 59.32% stake to Aamanya AG, it said in a filing on 29 Oct 2026. Both parties belong to the promoter group, and the company says the transfer leaves the group's overall holding unchanged.

    A block deal between two promoter group members

    Adimans Technologies LLP proposes to sell 9,30,02,442 equity shares, representing 59.32% of the paid-up share capital, to Aamanya AG by way of a block deal. The sale is set out in the share purchase agreement dated 28 Oct 2026.

    Sign up to continue reading

    Create a free account to read the rest of this article and the analysis that follows.

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Latest posts

    Add Blacklitt as preferred source